Oslo, Norway, 5 December 2011.
Please find attached the new Company presentation of PCI Biotech. The new presentation includes:
· An update of the company strategy
· Positive pre-clinical in vivo results with the cancer drugs docetaxel (Taxotere®), gemcitabine (Gemzar®) and erlotinib (Tarceva®).
Please find attached the new Company presentation of PCI Biotech. The new presentation includes:
· An update of the company strategy
· Positive pre-clinical in vivo results with the cancer drugs docetaxel (Taxotere®), gemcitabine (Gemzar®) and erlotinib (Tarceva®).
This company presentation will be held at Nordic Health Care Conference organized by DNB and Sigma Fondene 6 December 2011.
Kind regards,
Per Walday
CEO
Email: pw@pcibiotech.no
Mobil: +47 917 93 429
Kind regards,
Per Walday
CEO
Email: pw@pcibiotech.no
Mobil: +47 917 93 429
This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
